{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:07:45Z","timestamp":1792112865747,"version":"4.4.0"},"reference-count":232,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Individuals suffering from depressive disorders display a greater incidence of hypertension compared with the general population, despite reports of the association between depression and hypotension. This phenomenon may depend, at least in part, on the use of antidepressant drugs, which may influence blood pressure through different effects on adrenergic and serotoninergic pathways, as well as on histaminergic, dopaminergic, and cholinergic systems. This review summarizes extant literature on the effect of antidepressant drugs on blood pressure. Selective serotonin reuptake inhibitors are characterized by limited effects on autonomic system activity and a lower impact on blood pressure. Thus, they represent the safest class\u2014particularly among elderly and cardiovascular patients. Serotonin\u2013norepinephrine reuptake inhibitors, particularly venlafaxine, carry a greater risk of hypertension, possibly related to greater effects on the sympathetic nervous system. The norepinephrine reuptake inhibitor reboxetine is considered a safe option because of its neutral effects on blood pressure in long-term studies, even if both hypotensive and hypertensive effects are reported. The dopamine\u2013norepinephrine reuptake inhibitor bupropion can lead to blood pressure increases, usually at high doses, but may also cause orthostatic hypotension, especially in patients with cardiovascular diseases. The norepinephrine\u2013serotonin modulators, mirtazapine and mianserin, have minimal effects on blood pressure but may rarely lead to orthostatic hypotension and falls. These adverse effects are also observed with the serotonin-reuptake modulators, nefazodone and trazodone, but seldomly with vortioxetine and vilazodone. Agomelatine, the only melatonergic antidepressant drug, may also have limited effects on blood pressure. Tricyclic antidepressants have been associated with increases in blood pressure, as well as orthostatic hypotension, particularly imipramine. Oral monoamine\u2013oxidase inhibitors, less frequently skin patch formulations, have been associated with orthostatic hypotension or, conversely, with hypertensive crisis due to ingestion of tyramine-containing food (i.e., cheese reaction). Lastly, a hypertensive crisis may complicate antidepressant treatment as a part of the serotonin syndrome, also including neuromuscular, cognitive, and autonomic dysfunctions. Clinicians treating depressive patients should carefully consider their blood pressure status and cardiovascular comorbidities because of the effects of antidepressant drugs on blood pressure profiles and potential interactions with antihypertensive treatments.<\/jats:p>","DOI":"10.3389\/fcvm.2021.704281","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:31:13Z","timestamp":1627950673000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":127,"title":["Antidepressant Drugs Effects on Blood Pressure"],"prefix":"10.3389","volume":"8","author":[{"given":"Anna","family":"Calvi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Fischetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazio","family":"Verzicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martino","family":"Belvederi Murri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatula","family":"Zanetidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Volpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Coghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Amore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aderville","family":"Cabassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,3]]},"reference":[{"key":"B1","unstructured":"Depression and Other Common Mental Disorders: Global Health Estimates2017"},{"key":"B2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/515180a","article-title":"Mental health: a world of depression","volume":"515","author":"Smith","year":"2014","journal-title":"Nature."},{"key":"B3","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1097\/HJH.0b013e32835080b7","article-title":"Depression increases the risk of hypertension incidence: a meta-analysis of prospective cohort studies","volume":"30","author":"Meng","year":"2012","journal-title":"J Hypertens."},{"key":"B4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/PSY.0b013e3181988e5f","article-title":"Major depression as a risk factor for high blood pressure: epidemiologic evidence from a national longitudinal study","volume":"71","author":"Patten","year":"2009","journal-title":"Psychosom Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/archfami.6.1.43","article-title":"Are symptoms of anxiety and depression risk factors for hypertension? Longitudinal evidence from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study","volume":"6","author":"Jonas","year":"1997","journal-title":"Arch Fam Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1007\/s00213-019-05326-9","article-title":"Stress, sex hormones, inflammation, and major depressive disorder: Extending Social Signal Transduction Theory of Depression to account for sex differences in mood disorders","volume":"236","author":"Slavich","year":"2019","journal-title":"Psychopharmacology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3389\/fpsyt.2019.00541","article-title":"Gender disparity in the risk of hypertension in subjects with major depressive disorder","volume":"10","author":"Kao","year":"2019","journal-title":"Front Psychiatry."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1097\/HJH.0b013e32833e9d7c","article-title":"The combined influence of hypertension and common mental disorder on all-cause and cardiovascular disease mortality","volume":"28","author":"Hamer","year":"2010","journal-title":"J Hypertens."},{"key":"B10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0006-3223(03)00568-7","article-title":"Depression and cardiovascular disease: mechanisms of interaction","volume":"54","author":"Joynt","year":"2003","journal-title":"Biol Psychiatry."},{"key":"B11","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1161\/CIR.0000000000000229","article-title":"Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: a scientific statement from the American Heart Association","volume":"132","author":"Goldstein","year":"2015","journal-title":"Circulation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jagp.2016.08.005","article-title":"Physical exercise for late-life depression: effects on heart rate variability","volume":"24","author":"Toni","year":"2016","journal-title":"Am J Geriatr Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jad.2004.06.004","article-title":"Incident hypertension associated with depression in the Baltimore Epidemiologic Catchment area follow-up study","volume":"83","author":"Meyer","year":"2004","journal-title":"J Affect Disord."},{"key":"B14","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1161\/HYPERTENSIONAHA.109.139824","article-title":"Baseline depressive symptoms are not associated with clinically important levels of incident hypertension during two years of follow-up: the multi-ethnic study of atherosclerosis","volume":"55","author":"Delaney","year":"2010","journal-title":"Hypertension."},{"key":"B15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/EDE.0000000000000840","article-title":"Depressive symptoms, antidepressant use, and hypertension in young adulthood","volume":"29","author":"Crookes","year":"2018","journal-title":"Epidemiology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1161\/HYPERTENSIONAHA.108.126698","article-title":"Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension","volume":"53","author":"Licht","year":"2009","journal-title":"Hypertension."},{"key":"B17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1136\/jech.2005.044966","article-title":"Association of low blood pressure with anxiety and depression: the Nord-Tr\u00f8ndelag Health Study","volume":"61","author":"Hildrum","year":"2007","journal-title":"J Epidemiol Community Health."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/bph.13882","article-title":"The coincise guide to pharmacology 2017\/18: overview","volume":"174","author":"Alexander","year":"2017","journal-title":"Br J Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1124\/pr.111.004697","article-title":"Serotonin and blood pressure regulation","volume":"64","author":"Watts","year":"2012","journal-title":"Pharmacol Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.pharmthera.2005.12.004","article-title":"5-hydroxytryptamine receptors in the human cardiovascular system","volume":"111","author":"Kaumann","year":"2006","journal-title":"Pharmacol Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1210\/endo-125-5-2664","article-title":"Serotonin agonists cause parallel activation of the sympathoadrenomedullary system and the hypothalamo-pituitary-adrenocortical axis in conscious rats","volume":"125","author":"Bagdy","year":"1989","journal-title":"Endocrinology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"E513","DOI":"10.1152\/ajpendo.1996.270.3.E513","article-title":"Neuroendocrine and cardiovascular effects of serotonin: selective role of brain angiotensin on vasopressin","volume":"270","author":"Saydoff","year":"1996","journal-title":"Am J Physiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0361-9230(01)00612-8","article-title":"Central cardiovascular regulation and 5-hydroxytryptamine receptors","volume":"56","author":"Ramage","year":"2001","journal-title":"Brain Res Bull."},{"key":"B24","first-page":"S17","article-title":"Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning","volume":"11","author":"Dubini","year":"1997","journal-title":"J Psychopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/NDT.S19619","article-title":"The importance of norepinephrine in depression","volume":"7","author":"Moret","year":"2011","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/ijnp\/pyx056","article-title":"Dopamine system dysregulation in major depressive disorders","volume":"20","author":"Belujon","year":"2017","journal-title":"Int J Neuropsychopharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nrn.2016.57","article-title":"Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression","volume":"17","author":"Grace","year":"2016","journal-title":"Nat Rev Neurosci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3390\/biom11020254","article-title":"Dopamine receptors and the kidney: an overview of health- and pharmacological-targeted implications","volume":"11","author":"Olivares-Hern\u00e1ndez","year":"2021","journal-title":"Biomolecules."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1161\/CIR.0000000000000019","article-title":"Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association","volume":"129","author":"Lichtman","year":"2014","journal-title":"Circulation."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1093\/eurheartj\/ehy913","article-title":"Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation","volume":"41","author":"Vaccarino","year":"2020","journal-title":"Eur Heart J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1161\/01.CIR.93.11.1976","article-title":"Symptoms of depression, acute myocardial infarction, and total mortality in a community sample","volume":"93","author":"Barefoot","year":"1996","journal-title":"Circulation."},{"key":"B32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3109\/10253890.2015.1045868","article-title":"Autonomic dysfunction and heart rate variability in depression","volume":"18","author":"Sgoifo","year":"2015","journal-title":"Stress."},{"key":"B33","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jad.2019.01.043","article-title":"Complex cardiac vagal regulation to mental and physiological stress in adolescent major depression","volume":"249","author":"Mestanikova","year":"2019","journal-title":"J Affect Disord."},{"key":"B34","doi-asserted-by":"publisher","first-page":"112802","DOI":"10.1016\/j.psychres.2020.112802","article-title":"Depression and cardiovascular disease: shared molecular mechanisms and clinical implications","volume":"285","author":"Shao","year":"2020","journal-title":"Psychiatry Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1570161043476483","article-title":"Glucocorticoids and vascular reactivity","volume":"2","author":"Yang","year":"2004","journal-title":"Curr Vasc Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/FJC.0000000000000187","article-title":"Role of peripheral vascular resistance for the association between major depression and cardiovascular disease","volume":"65","author":"Bouzinova","year":"2015","journal-title":"J Cardiovasc Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/01.psy.0000160467.78373.d8","article-title":"Depressive symptoms are associated with increased systemic vascular resistance to stress","volume":"67","author":"Matthews","year":"2005","journal-title":"Psychosom Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0002-9149(01)01623-X","article-title":"Abnormal brachial artery flow-mediated vasodilation in young adults with major depression","volume":"88","author":"Rajagopalan","year":"2001","journal-title":"Am J Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.biopsycho.2008.11.001","article-title":"Intima-media thickness and age of first depressive episode","volume":"80","author":"Smith","year":"2009","journal-title":"Biol Psychol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/gerona\/gls230","article-title":"Depression treatment selectively modifies arterial stiffness in older participants","volume":"68","author":"Scuteri","year":"2013","journal-title":"J Gerontol A Biol Sci Med Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jad.2019.04.024","article-title":"The effect of treatment response on endothelial function and arterial stiffness in depression. A prospective study","volume":"252","author":"Kokras","year":"2019","journal-title":"J Affect Disord."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1161\/HYPERTENSIONAHA.120.15605","article-title":"Antihypertensive drugs and risk of depression: a nationwide population-based study","volume":"76","author":"Kessing","year":"2020","journal-title":"Hypertension."},{"key":"B43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ahj.2015.11.018","article-title":"Initiation of \u03b2-blocker therapy and depression after acute myocardial infarction","volume":"174","author":"Ranchord","year":"2016","journal-title":"Am Heart J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41371-020-0303-y","article-title":"The association of antihypertensive use and depressive symptoms in a large older population with hypertension living in Australia and the United States: a cross-sectional study","volume":"34","author":"Agustini","year":"2020","journal-title":"J Hum Hypertens."},{"key":"B45","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1067\/mcp.2000.104788","article-title":"Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"67","author":"Hemeryck","year":"2000","journal-title":"Clin Pharmacol Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1592\/phco.31.7.630","article-title":"Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol","volume":"31","author":"Parker","year":"2011","journal-title":"Pharmacotherapy."},{"key":"B47","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/0091270010365559","article-title":"Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine","volume":"51","author":"Stout","year":"2011","journal-title":"J Clin Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/archinte.162.4.405","article-title":"Implications of cytochrome P450 interactions when prescribing medication for hypertension","volume":"162","author":"Flockhart","year":"2002","journal-title":"Arch Intern Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1590\/S0102-311X2009001000013","article-title":"Interactions between antidepressants and antihypertensive and glucose lowering drugs among patients in the HIPERDIA Program, Coronel Fabriciano, Minas Gerais State, Brazil","volume":"25","author":"Coelho","year":"2009","journal-title":"Cad Saude Publica."},{"key":"B50","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2165\/00002512-200219040-00004","article-title":"Clinically significant drug interactions with antidepressants in the elderly","volume":"19","author":"Spina","year":"2002","journal-title":"Drugs Aging."},{"key":"B51","doi-asserted-by":"publisher","first-page":"158","DOI":"10.15386\/mpr-1225","article-title":"Pharmacokinetic interactions study between carvedilol and some antidepressants in rat liver microsomes - a comparative study","volume":"92","author":"Abrudan","year":"2019","journal-title":"Med Pharm Rep."},{"key":"B52","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2165\/11594710-000000000-00000","article-title":"Clinically significant drug interactions with newer antidepressants","volume":"26","author":"Spina","year":"2012","journal-title":"CNS Drugs"},{"key":"B53","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.pcad.2015.11.003","article-title":"Treatment of depression in patients with concomitant cardiac disease","volume":"58","author":"Teply","year":"2016","journal-title":"Prog Cardiovasc Dis."},{"key":"B54","first-page":"409","article-title":"Influence of mianserin on the activity of some hypotensive drugs in spontaneously hypertensive rats","volume":"55","author":"G\u00f3rska","year":"2003","journal-title":"Pol J Pharmacol."},{"key":"B55","first-page":"28","volume-title":"Essential Psychopharmacology. Neuroscientific Basis and Practical Applications","author":"Stahl","year":"2013"},{"key":"B56","doi-asserted-by":"publisher","first-page":"977","DOI":"10.12740\/PP\/OnlineFirst\/96286","article-title":"Adverse effects of interactions between antidepressants and medications used in treatment of cardiovascular disorders","volume":"53","author":"Woro\u0144","year":"2019","journal-title":"Psychiatr Pol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/j.1524-6175.2006.05939.x","article-title":"Drug interactions and drugs that affect blood pressure","volume":"8","author":"Elliott","year":"2006","journal-title":"J Clin Hypertens."},{"key":"B58","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1177\/0269881115581093","article-title":"Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines","volume":"29","author":"Cleare","year":"2015","journal-title":"J Psychopharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1046\/j.0306-5251.2001.01426.x","article-title":"Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction","volume":"52","author":"Meier","year":"2001","journal-title":"Br J Clin Pharmacol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1345\/aph.1C071","article-title":"Citalopram-associated SIADH","volume":"36","author":"Barclay","year":"2002","journal-title":"Ann Pharmacother."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/bcp.13194","article-title":"SSRI and SNRI use during pregnancy and the risk of persistent pulmonary hypertension of the newborn","volume":"83","author":"B\u00e9rard","year":"2017","journal-title":"Br J Clin Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/00004872-200018020-00009","article-title":"Effect of antioxidant treatments on nitrate tolerance development in normotensive and hypertensive rats","volume":"18","author":"Cabassi","year":"2000","journal-title":"J Hypertens."},{"key":"B63","doi-asserted-by":"publisher","first-page":"761567","DOI":"10.1155\/2013\/761567","article-title":"Venlafaxine-induced orthostatic hypotension in a geriatric patient","volume":"2013","author":"Chikkaramanjegowda","year":"2013","journal-title":"Case Rep Psychiatry."},{"key":"B64","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1097\/01.JGP.0000204328.50105.b3","article-title":"Cardiovascular changes associated with venlafaxine in the treatment of late-life depression","volume":"14","author":"Johnson","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"key":"B65","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/JGP.0b013e3180488358","article-title":"Cardiovascular changes associated with venlafaxine in the treatment of late-life depression","volume":"15","author":"Kok","year":"2007","journal-title":"Am J Geriatr Psychiatry."},{"key":"B66","first-page":"371","article-title":"Venlafaxine - induced orthostatic hypotension","volume":"43","author":"Duggal","year":"2001","journal-title":"Indian J Psychiatry."},{"key":"B67","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s13181-011-0167-1","article-title":"Cardiotoxicity and serotonin syndrome complicating a milnacipran overdose","volume":"7","author":"Levine","year":"2011","journal-title":"J Med Toxicol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/JCP.0b013e318172424e","article-title":"A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension","volume":"28","author":"Thase","year":"2008","journal-title":"J Clin Psychopharmacol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5694\/j.1326-5377.2003.tb05064.x","article-title":"Bupropion poisoning: a case series","volume":"178","author":"Balit","year":"2003","journal-title":"Med J Aust."},{"key":"B70","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1365-2125.1983.tb01512.x","article-title":"Effects of bupropion, nomifensine and dexamphetamine on performance, subjective feelings, autonomic variables and electroencephalogram in healthy volunteers","volume":"15","author":"Hamilton","year":"1983","journal-title":"Br J Clin Pharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1053\/ajem.2000.9287","article-title":"Toxicities and outcomes associated with nefazodone poisoning: an analysis of 1,338 exposures","volume":"18","author":"Benson","year":"2000","journal-title":"Am J Emerg Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1592\/phco.23.6.754.32185","article-title":"Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature","volume":"23","author":"Alvar Alvarez W","year":"2003","journal-title":"Pharmacotherapy."},{"key":"B73","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1001\/jama.297.4.367","article-title":"Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial","volume":"297","author":"Lesp\u00e9rance","year":"2007","journal-title":"JAMA."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.euroneuro.2013.05.011","article-title":"The cardiovascular safety profile of escitalopram","volume":"23","author":"Thase","year":"2013","journal-title":"Eur Neuropsychopharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.jocn.2015.03.067","article-title":"Antidepressant medication can improve hypertension in elderly patients with depression","volume":"22","author":"Fu","year":"2015","journal-title":"J Clin Neurosci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/gps.1190","article-title":"Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram","volume":"19","author":"Allard","year":"2004","journal-title":"Int J Geriatr Psychiatry."},{"key":"B77","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1080\/10641963.2018.1501058","article-title":"Effects of SSRI medication on heart rate and blood pressure in individuals with hypertension and depression","volume":"41","author":"Peixoto","year":"2019","journal-title":"Clin Exp Hypertens."},{"key":"B78","doi-asserted-by":"publisher","first-page":"148","DOI":"10.4306\/pi.2013.10.2.148","article-title":"Relationship between SSRIs and metabolic syndrome abnormalities in patients with generalized anxiety disorder: a prospective study","volume":"10","author":"Beyazy\u00fcz","year":"2013","journal-title":"Psychiatry Investig."},{"key":"B79","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jama.279.4.287","article-title":"Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease","volume":"279","author":"Roose","year":"1998","journal-title":"JAMA."},{"key":"B80","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00213-005-0075-7","article-title":"Effects of paroxetine on cardiovascular response to mental stress in subjects with a history of coronary artery disease and no psychiatric diagnoses","volume":"182","author":"Golding","year":"2005","journal-title":"Psychopharmacology."},{"key":"B81","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/PSY.0b013e3182898f6d","article-title":"Effect of paroxetine on physiological response to stress and smoking","volume":"75","author":"Kotlyar","year":"2013","journal-title":"Psychosom Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0306-4522(00)00014-2","article-title":"Immunocytochemical localization of the sigma(1) receptor in the adult rat central nervous system","volume":"97","author":"Alonso","year":"2000","journal-title":"Neuroscience."},{"key":"B83","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jphs.2014.11.010","article-title":"Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication","volume":"127","author":"Hashimoto","year":"2015","journal-title":"J Pharmacol Sci."},{"key":"B84","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/jch.13197","article-title":"Systolic blood pressure as a potential target of sigma-1 receptor agonist therapy","volume":"20","author":"Cohen","year":"2018","journal-title":"J Clin Hypertens (Greenwich)."},{"key":"B85","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/jama.288.6.701","article-title":"Sertraline treatment of major depression in patients with acute MI or unstable angina","volume":"288","author":"Glassman","year":"2002","journal-title":"JAMA."},{"key":"B86","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0278-5846(00)00168-8","article-title":"Clinical and treatment response characteristics of late-life depression associated with vascular disease: a pooled analysis of two multicenter trials with sertraline","volume":"25","author":"Krishnan","year":"2001","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1177\/1060028013501994","article-title":"A comparison of the risk of QT prolongation among SSRIs","volume":"47","author":"Funk","year":"2013","journal-title":"Ann Pharmacother."},{"key":"B88","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/00004714-199902000-00004","article-title":"Blood pressure changes during short-term fluoxetine treatment","volume":"19","author":"Amsterdam","year":"1999","journal-title":"J Clin Psychopharmacol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/00006842-200011000-00007","article-title":"Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial","volume":"62","author":"Strik","year":"2000","journal-title":"Psychosom Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.2147\/NDT.S141832","article-title":"A meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials","volume":"13","author":"Zhong","year":"2017","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B91","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.vph.2017.07.004","article-title":"Effects of psychopharmacological treatment with antidepressants on the vascular system","author":"Kahl","year":"2017","journal-title":"Vascul Pharmacol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1365-2885.2008.00944.x","article-title":"Serotonin: a review","volume":"31","author":"Mohammad-Zadeh","year":"2008","journal-title":"J Vet Pharmacol Ther."},{"key":"B93","doi-asserted-by":"publisher","first-page":"2045125318818814","DOI":"10.1177\/2045125318818814","article-title":"Management of severe arterial hypertension associated with serotonin syndrome: a case report analysis based on systematic review techniques","volume":"9","author":"Ott","year":"2019","journal-title":"Ther Adv Psychopharmacol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"e236450","DOI":"10.1136\/bcr-2020-236450","article-title":"Posterior reversible encephalopathy syndrome in a patient with serotonin syndrome","volume":"13","author":"Prakash","year":"2020","journal-title":"BMJ Case Rep."},{"key":"B95","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0736-4679(98)00057-2","article-title":"Treatment of the serotonin syndrome with cyproheptadine","volume":"16","author":"Graudins","year":"1998","journal-title":"J Emerg Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.109.133272","article-title":"Depression and blood pressure control: all antidepressants are not the same","volume":"54","author":"Dawood","year":"2009","journal-title":"Hypertension."},{"key":"B97","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12884-018-1825-y","article-title":"Antidepressant use during pregnancy and the risk of developing gestational hypertension: a retrospective cohort study","volume":"18","author":"Zakiyah","year":"2018","journal-title":"BMC Pregnancy Childbirth."},{"key":"B98","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12884-019-2285-8","article-title":"Use of antidepressants and anxiolytics in early pregnancy and the risk of preeclampsia and gestational hypertension: a prospective study","volume":"19","author":"Bernard","year":"2019","journal-title":"BMC Pregnancy Childbirth."},{"key":"B99","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1176\/appi.ajp.2008.08060817","article-title":"Selective serotonin reuptake inhibitor use and risk of gestational hypertension","volume":"166","author":"Toh","year":"2009","journal-title":"Am J Psychiatry."},{"key":"B100","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1017\/S1461145705006413","article-title":"Differential physiological effects of a low dose and high doses of venlafaxine in major depression","volume":"10","author":"Debonnel","year":"2007","journal-title":"Int J Neuropsychopharmacol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/ijnp\/pyz003","article-title":"Venlafaxine ER blocks the norepinephrine transporter in the brain of patients with major depressive disorder: a pet study using [18F]FMeNER-D2","volume":"22","author":"Arakawa","year":"2019","journal-title":"Int J Neuropsychopharmacol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/CE.S5998","article-title":"Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy","volume":"4","author":"Lieberman","year":"2010","journal-title":"Core Evid."},{"key":"B103","doi-asserted-by":"publisher","first-page":"E29","DOI":"10.1176\/appi.neuropsych.12030074","article-title":"Desvenlafaxine-induced worsening of hypertension","volume":"25","author":"Munoli","year":"2013","journal-title":"J Neuropsychiatry Clin Neurosci."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1177\/0269881120944154","article-title":"Hypertension and orthostatic hypotension with venlafaxine treatment in depressed older adults","author":"Wathra","year":"2020","journal-title":"J Psychopharmacol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1159\/000447034","article-title":"The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature","volume":"85","author":"Carvalho","year":"2016","journal-title":"Psychother Psychosom."},{"key":"B106","doi-asserted-by":"publisher","first-page":"502","DOI":"10.4088\/JCP.v59n1002","article-title":"Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients","volume":"59","author":"Thase","year":"1998","journal-title":"J Clin Psychiatry."},{"key":"B107","doi-asserted-by":"publisher","first-page":"659715","DOI":"10.1155\/2014\/659715","article-title":"Accelerated hypertension after venlafaxine usage","volume":"2014","author":"Kivrak","year":"2014","journal-title":"Case Rep Psychiatry."},{"key":"B108","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S0002-9343(03)00472-8","article-title":"Hypertensive crisis associated with venlafaxine","volume":"115","author":"Khurana","year":"2003","journal-title":"Am J Med."},{"key":"B109","first-page":"574","article-title":"Cardiovascular safety in depressed patients: focus on venlafaxine","volume":"56","author":"Feighner","year":"1995","journal-title":"J Clin Psychiatry."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1185\/03007990802161923","article-title":"Efficacy, safety, and tolerability of desvenlafaxine 50 mg\/day and 100 mg\/day in outpatients with major depressive disorder","volume":"24","author":"Liebowitz","year":"2008","journal-title":"Curr Med Res Opin."},{"key":"B111","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1089\/cap.2012.0126","article-title":"Safety and tolerability of desvenlafaxine in children and adolescents with major depressive disorder","volume":"24","author":"Findling","year":"2014","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40064-015-0883-0","article-title":"Venlafaxine as single therapy associated with hypertensive encephalopathy","volume":"4","author":"Edvardsson","year":"2015","journal-title":"Springerplus."},{"key":"B113","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1440-1797.2007.00853.x","article-title":"Venlafaxine to treat severe hypotension","volume":"12","author":"Agarwal","year":"2007","journal-title":"Nephrology."},{"key":"B114","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1161\/CIR.0000000000000538","article-title":"2017 ACC\/AHA\/HRS guideline for the evaluation and management of patients with syncope: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"136","author":"Shen","year":"2017","journal-title":"Circulation."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.5603\/KP.2018.0161","article-title":"2018 ESC guidelines for the diagnosis and management of syncope","volume":"39","author":"Brignole","year":"2018","journal-title":"Eur Heart J."},{"key":"B116","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3389\/fpsyt.2019.00772","article-title":"Duloxetine in psychiatric disorders: expansions beyond major depression and generalized anxiety disorder","volume":"10","author":"Muscatello","year":"2019","journal-title":"Front Psychiatry."},{"key":"B117","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/01.jcp.0000155815.44338.95","article-title":"Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine","volume":"25","author":"Thase","year":"2005","journal-title":"J Clin Psychopharmacol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jpsychires.2020.02.022","article-title":"Duloxetine and cardiovascular adverse events: a systematic review and meta-analysis","volume":"124","author":"Park","year":"2020","journal-title":"J Psychiatr Res."},{"key":"B119","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jagp.2013.01.019","article-title":"Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo","volume":"22","author":"Robinson","year":"2014","journal-title":"Am J Geriatr Psychiatry."},{"key":"B120","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/hup.696","article-title":"Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials","volume":"20","author":"Hudson","year":"2005","journal-title":"Hum Psychopharmacol."},{"key":"B121","first-page":"573","article-title":"Takotsubo cardiomyopathy associated with titration of duloxetine","volume":"38","author":"Selke","year":"2011","journal-title":"Tex Heart Inst J."},{"key":"B122","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.euroneuro.2010.03.009","article-title":"Broken heart syndrome: Tako Tsubo cardiomyopathy associated with an overdose of the serotonin-norepinephrine reuptake inhibitor Venlafaxine","volume":"20","author":"Christoph","year":"2010","journal-title":"Eur Neuropsychopharmacol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/jcp.0b013e318160738e","article-title":"Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder","volume":"28","author":"Raskin","year":"2008","journal-title":"J Clin Psychopharmacol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s40263-020-00763-z","article-title":"The cardiovascular effects of newer antidepressants in older adults and those with or at high risk for cardiovascular diseases","volume":"34","author":"Behlke","year":"2020","journal-title":"CNS Drugs."},{"key":"B125","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1177\/0269881107076403","article-title":"Hypotension caused by therapeutic doses of venlafaxine: case report and proposed pathophysiological mechanisms","volume":"22","author":"Alexandrino-Silva","year":"2008","journal-title":"J Psychopharmacol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"38518","DOI":"10.1074\/jbc.M004550200","article-title":"An asn to lys polymorphism in the third intracellular loop of the human alpha 2A-adrenergic receptor imparts enhanced agonist-promoted Gi coupling","volume":"275","author":"Small","year":"2000","journal-title":"J Biol Chem."},{"key":"B127","doi-asserted-by":"publisher","first-page":"11946","DOI":"10.1021\/bi00037a036","article-title":"An acidic motif within the third intracellular loop of the alpha2C2 adrenergic receptor is required for agonist-promoted phosphorylation and desensitization","volume":"34","author":"Jewell-Motz","year":"1995","journal-title":"Biochemistry."},{"key":"B128","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ijcard.2003.10.014","article-title":"Clinical and pharmacological significance of alpha2-adrenoceptor polymorphisms in cardiovascular diseases","volume":"97","author":"Flordellis","year":"2004","journal-title":"Int J Cardiol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/WNF.0b013e3181ac155b","article-title":"Milnacipran: beyond a role of antidepressant","volume":"32","author":"Pae","year":"2009","journal-title":"Clin Neuropharmacol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.neuropharm.2013.02.024","article-title":"Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety","volume":"70","author":"Auclair","year":"2013","journal-title":"Neuropharmacology."},{"key":"B131","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2174\/1570159X14666151117122458","article-title":"The role of levomilnacipran in the management of major depressive disorder: a comprehensive review","volume":"14","author":"Bruno","year":"2016","journal-title":"Curr Neuropharmacol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1345\/aph.1P218","article-title":"Milnacipran for treatment of fibromyalgia","volume":"44","author":"Kyle","year":"2010","journal-title":"Ann Pharmacother."},{"key":"B133","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/NDT.S54710","article-title":"Levomilnacipran for the treatment of major depressive disorder: a review","volume":"11","author":"Asnis","year":"2015","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B134","doi-asserted-by":"publisher","first-page":"242","DOI":"10.4088\/JCP.12m08197","article-title":"Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study","volume":"74","author":"Asnis","year":"2013","journal-title":"J Clin Psychiatry."},{"key":"B135","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40261-013-0126-5","article-title":"Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study","volume":"33","author":"Mago","year":"2013","journal-title":"Clin Drug Investig."},{"key":"B136","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/JCP.0000000000000060","article-title":"A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder","volume":"34","author":"Sambunaris","year":"2014","journal-title":"J Clin Psychopharmacol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.2147\/NDT.S114955","article-title":"Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder","volume":"12","author":"Huang","year":"2016","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B138","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1055\/s-2006-958723","article-title":"Hypertension induced by regular doses of milnacipran: a case report","volume":"40","author":"de Toledo Ferraz Alves","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"B139","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/hup.432","article-title":"Elevation of blood pressure induced by high-dose milnacipran","volume":"17","author":"Yoshida","year":"2002","journal-title":"Hum Psychopharmacol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1185\/03007995.2013.861812","article-title":"Milnacipran effects on 24-h ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study","volume":"30","author":"Trugman","year":"2014","journal-title":"Curr Med Res Opin."},{"key":"B141","first-page":"714","article-title":"Hypertension, tachycardia, and reversible cardiomyopathy temporally associated with milnacipran use","volume":"38","author":"Forman","year":"2011","journal-title":"Tex Heart Inst J."},{"key":"B142","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0165-0327(99)00073-7","article-title":"Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial","volume":"55","author":"Katona","year":"1999","journal-title":"J Affect Disord."},{"key":"B143","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/sj.bjp.0703821","article-title":"Chronic treatment with reboxetine by osmotic pumps facilitates its effect on extracellular noradrenaline and may desensitize alpha(2)-adrenoceptors in the prefrontal cortex","volume":"132","author":"Invernizzi","year":"2001","journal-title":"Br J Pharmacol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.taap.2012.09.010","article-title":"Improved preclinical cardiovascular therapeutic indices with long-term inhibition of norepinephrine reuptake using reboxetine","volume":"264","author":"Fossa","year":"2012","journal-title":"Toxicol Appl Pharmacol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/S0006-3223(99)00291-7","article-title":"Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor","volume":"47","author":"Wong","year":"2000","journal-title":"Biol Psychiatry."},{"key":"B146","first-page":"195","article-title":"Effectiveness of reboxetine in treatment of outpatient children and adolescents with attention deficit-hyperactivity disorder with comorbid anxiety disorders","volume":"8","author":"Riahi","year":"2013","journal-title":"Iran J Psychiatry."},{"key":"B147","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00213-002-1146-7","article-title":"Effects of reboxetine, a selective norepinephrine reuptake inhibitor, on sympathetic and parasympathetic outflow to the heart: preliminary data","volume":"163","author":"Agelink","year":"2002","journal-title":"Psychopharmacology."},{"key":"B148","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1161\/hc0302.102597","article-title":"Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance","volume":"105","author":"Schroeder","year":"2002","journal-title":"Circulation."},{"key":"B149","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s002130000664","article-title":"The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system. A randomised placebo-controlled study on healthy volunteers","volume":"154","author":"Penttil\u00e4","year":"2001","journal-title":"Psychopharmacology."},{"key":"B150","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S0009-9236(99)70036-6","article-title":"Hemodynamic effects of reboxetine in healthy male volunteers","volume":"66","author":"Denolle","year":"1999","journal-title":"Clin Pharmacol Ther."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1345\/aph.19335","article-title":"Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression","volume":"34","author":"Scates","year":"2000","journal-title":"Ann Pharmacother."},{"key":"B152","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00406-010-0164-4","article-title":"The effect of a 4-week treatment with reboxetine on metabolic parameters of depressed inpatients","volume":"261","author":"Paslakis","year":"2011","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"B153","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10286-015-0271-4","article-title":"Multiple system atrophy: using clinical pharmacology to reveal pathophysiology","volume":"25","author":"Jordan","year":"2015","journal-title":"Clin Auton Res."},{"key":"B154","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3109\/10401239409148989","article-title":"The cardiovascular effects of bupropion and nortriptyline in depressed outpatients","volume":"6","author":"Kiev","year":"1994","journal-title":"Ann Clin Psychiatry."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.amjmed.2006.04.024","article-title":"Bupropion for smokers hospitalized with acute cardiovascular disease","volume":"119","author":"Rigotti","year":"2006","journal-title":"Am J Med."},{"key":"B156","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1177\/0269881108100254","article-title":"Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder","volume":"24","author":"Hewett","year":"2010","journal-title":"J Psychopharmacol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1001\/archinternmed.2011.72","article-title":"Bupropion for smoking cessation in patients with acute coronary syndrome","volume":"171","author":"Planer","year":"2011","journal-title":"Arch Intern Med"},{"key":"B158","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0736-4679(02)00522-X","article-title":"Bupropion exposures: clinical manifestations and medical outcome","volume":"23","author":"Belson","year":"2002","journal-title":"J Emerg Med."},{"key":"B159","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1176\/ajp.148.4.512","article-title":"Cardiovascular effects of bupropion in depressed patients with heart disease","volume":"148","author":"Roose","year":"1991","journal-title":"Am J Psychiatry."},{"key":"B160","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2125.1983.tb05881.x","article-title":"Assessment of the interaction between mianserin and centrally-acting antihypertensive drugs","volume":"15","author":"Elliott","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/BF00427964","article-title":"Mianserin: cardiovascular effects in elderly patients","volume":"80","author":"M\u00f8ller","year":"1983","journal-title":"Psychopharmacology."},{"key":"B162","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/01.HDX.0000061695.97215.64","article-title":"Cardiovascular effects of selective serotonin reuptake inhibitors and other novel antidepressants","volume":"5","year":"2003","journal-title":"Heart Dis."},{"key":"B163","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2165\/00003495-199957040-00010","article-title":"Mirtazapine: a review of its use in major depression","volume":"57","author":"Holm","year":"1999","journal-title":"Drugs."},{"key":"B164","doi-asserted-by":"publisher","first-page":"144","DOI":"10.9758\/cpn.2015.13.2.144","article-title":"Efficacy and tolerability of generic mirtazapine (Mirtax) for major depressive disorder: multicenter, open-label, uncontrolled, prospective study","volume":"13","author":"Song","year":"2015","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"B165","first-page":"51","article-title":"Ocena wp\u0142ywu mianseryny na wskazniki hemodynamiczne u chorych z depresja endogenna [Evaluation of the effect of mianserin on hemodynamic indicators in patients with endogenous depression]","volume":"25","author":"Jakitowicz","year":"1991","journal-title":"Psychiatr Pol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/BF00542488","article-title":"Mianserin and trazodone for cardiac patients with depression","volume":"33","author":"Bucknall","year":"1988","journal-title":"Eur J Clin Pharmacol."},{"key":"B167","doi-asserted-by":"crossref","first-page":"29S","DOI":"10.1111\/j.1365-2125.1978.tb04572.x","article-title":"Anticholinergic and blood pressure effects of mianserin, amitriptyline and placebo","volume":"5","author":"Kopera","year":"1978","journal-title":"Br J Clin Pharmacol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2165\/00002512-199813040-00003","article-title":"Choosing appropriate antidepressant therapy in the elderly. A risk-benefit assessment of available agents","volume":"13","author":"Flint","year":"1998","journal-title":"Drugs Aging."},{"key":"B169","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/BF00542048","article-title":"A pharmacokinetic study of mianserin","volume":"21","author":"Maguire","year":"1982","journal-title":"Eur J Clin Pharmacol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0165-0327(99)00202-5","article-title":"Autonomic neurocardiac function in patients with major depression and effects of antidepressive treatment with nefazodone","volume":"62","author":"Agelink","year":"2001","journal-title":"J Affect Disord."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s40263-012-0010-5","article-title":"Rediscovering trazodone for the treatment of major depressive disorder","volume":"26","author":"Fagiolini","year":"2012","journal-title":"CNS Drugs."},{"key":"B172","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1179\/acb.2001.038","article-title":"Fatal overdose with trazodone: case report and literature review","volume":"56","author":"de Meester","year":"2001","journal-title":"Acta Clin Belg."},{"key":"B173","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/BF00605991","article-title":"The electrocardiographic and anticholinergic effects of trazodone and imipramine in man","volume":"23","author":"Burgess","year":"1982","journal-title":"Eur J Clin Pharmacol."},{"key":"B174","first-page":"272","article-title":"The newer antidepressant drugs and their cardiovascular effects","volume":"20","author":"Glassman","year":"1984","journal-title":"Psychopharmacol Bull."},{"key":"B175","doi-asserted-by":"publisher","first-page":"2470592","DOI":"10.1155\/2019\/2470592","article-title":"Management of trazodone overdose with severe hypotension","volume":"2019","author":"Camacho","year":"2019","journal-title":"Case Rep Emerg Med."},{"key":"B176","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/0269881116628440","article-title":"The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies","volume":"30","author":"Baldwin","year":"2016","journal-title":"J Psychopharmacol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2174\/1745017901511010144","article-title":"Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option?","volume":"11","author":"Carta","year":"2015","journal-title":"Clin Pract Epidemiol Ment Health."},{"key":"B178","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2165\/11207550-000000000-00000","article-title":"Vilazodone: in major depressive disorder","volume":"25","author":"Frampton","year":"2011","journal-title":"CNS Drugs."},{"key":"B179","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1517\/14656566.2016.1133588","article-title":"Vortioxetine: a new treatment for major depressive disorder","volume":"17","author":"Connolly","year":"2016","journal-title":"Expert Opin Pharmacother."},{"key":"B180","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1517\/17460441.2016.1160051","article-title":"The preclinical and clinical effects of vilazodone for the treatment of major depressive disorder","volume":"11","author":"Sahli","year":"2016","journal-title":"Expert Opin Drug Discov."},{"key":"B181","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/biolre\/iox115","article-title":"Maternal melatonin or agomelatine therapy prevents programmed hypertension in male offspring of mother exposed to continuous light","volume":"97","author":"Tain","year":"2017","journal-title":"Biol Reprod."},{"key":"B182","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1161\/01.HYP.0000113293.15186.3b","article-title":"Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension","volume":"43","author":"Scheer","year":"2004","journal-title":"Hypertension."},{"key":"B183","unstructured":"1317Agomelatine and Hypertension2014"},{"key":"B184","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002512-200926050-00002","article-title":"Antidepressants and falls in the elderly","volume":"26","author":"Darowski","year":"2009","journal-title":"Drugs Aging."},{"key":"B185","first-page":"509","article-title":"Incidence of orthostatic hypotension in patients with primary affective disorders treated with tricyclic antidepressants","volume":"52","author":"Hayes","year":"1977","journal-title":"Mayo Clin Proc."},{"key":"B186","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/archpsyc.1981.01780320095011","article-title":"Cardiovascular effects of therapeutic doses of tricyclic antidepressants. A review","volume":"38","author":"Glassman","year":"1981","journal-title":"Arch Gen Psychiatry"},{"key":"B187","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/00007691-200108000-00019","article-title":"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients","volume":"23","author":"Rodriguez de la Torre","year":"2001","journal-title":"Ther Drug Monit."},{"key":"B188","doi-asserted-by":"publisher","first-page":"CD002317","DOI":"10.1002\/14651858.CD002317.pub2","article-title":"Tricyclic drugs for depression in children and adolescents","volume":"2013","author":"Hazell","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"key":"B189","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1600-0447.2008.01260.x","article-title":"Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety","volume":"118","author":"Taylor","year":"2008","journal-title":"Acta Psychiatr Scand."},{"key":"B190","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/jhh.2013.82","article-title":"Alcohol and psychotropic drugs: risk factors for orthostatic hypotension in elderly fallers","volume":"31","author":"Gaxatte","year":"2017","journal-title":"J Hum Hypertens."},{"key":"B191","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/268455a0","article-title":"Development of beta-adrenergic receptor subsensitivity by antidepressants","volume":"268","author":"Banerjee","year":"1977","journal-title":"Nature."},{"key":"B192","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0014-2999(80)90126-0","article-title":"Effects of chronic desipramine treatment on rat brain noradrenergic responses to alpha-adrenergic drugs","volume":"61","author":"McMillen","year":"1980","journal-title":"Eur J Pharmacol."},{"key":"B193","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1001\/jama.257.4.521","article-title":"Tricyclic antidepressant overdose. A review","volume":"257","author":"Frommer","year":"1987","journal-title":"JAMA"},{"key":"B194","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/0735-6757(88)90241-0","article-title":"Hypotension in severe tricyclic antidepressant overdose","volume":"6","author":"Shannon","year":"1988","journal-title":"Am J Emerg Med"},{"key":"B195","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1136\/emj.18.4.236","article-title":"Tricyclic antidepressant overdose: a review","volume":"18","author":"Kerr","year":"2001","journal-title":"Emerg Med J."},{"key":"B196","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/0014-2999(75)90297-6","article-title":"Tricyclic antidepressants: effects on the firing rate of brain noradrenergic neurons","volume":"32","author":"Nyb\u00e4ck","year":"1975","journal-title":"Eur J Pharmacol."},{"key":"B197","doi-asserted-by":"publisher","first-page":"pyu080","DOI":"10.1093\/ijnp\/pyu080","article-title":"Cardiovascular adverse reactions during antidepressant treatment: a drug surveillance report of German-speaking countries between 1993 and 2010","volume":"18","author":"Spindelegger","year":"2014","journal-title":"Int J Neuropsychopharmacol."},{"key":"B198","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/BF00432748","article-title":"Cardiovascular effect of imipramine and nortriptyline in elderly patients","volume":"74","author":"Thayssen","year":"1981","journal-title":"Psychopharmacology."},{"key":"B199","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(79)90824-9","article-title":"Clinical characteristics of imipramine-induced orthostatic hypotension","volume":"1","author":"Glassman","year":"1979","journal-title":"Lancet."},{"key":"B200","doi-asserted-by":"publisher","first-page":"411S","DOI":"10.1111\/j.1365-2125.1983.tb02131.x","article-title":"A double-blind controlled clinical trial comparing fluvoxamine with imipramine","volume":"15","author":"Guelfi","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"B201","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/BF00427895","article-title":"Orthostatic side effects of clomipramine and citalopram during treatment for depression","volume":"86","author":"Christensen","year":"1985","journal-title":"Psychopharmacology."},{"key":"B202","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1053\/cp.1999.v66.99720","article-title":"Danish University Antidepressant Group (DUAG)","volume":"66","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"B203","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1034\/j.1600-0447.2002.0_001.x_001.x","article-title":"Age-related adverse drug reactions to clomipramine","volume":"105","author":"Stage","year":"2002","journal-title":"Acta Psychiatr Scand"},{"key":"B204","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/BF00547046","article-title":"A comparison of the cardiovascular effects and subjective tolerability of binedaline and amitriptylene in healthy volunteers","volume":"27","author":"Joubert","year":"1985","journal-title":"Eur J Clin Pharmacol."},{"key":"B205","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4103\/0019-5545.55952","article-title":"Efficacy and safety of citalopram versus amitriptyline in the treatment of major depression","volume":"47","author":"Mathur","year":"2005","journal-title":"Indian J Psychiatry."},{"key":"B206","doi-asserted-by":"publisher","first-page":"385S","DOI":"10.1111\/j.1365-2125.1983.tb02129.x","article-title":"A double-blind placebo-controlled study to compare the autonomic effects of fluvoxamine with those of amitriptyline and doxepin in healthy volunteers","volume":"15","author":"Wilson","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"B207","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/BF00314863","article-title":"A comparison of the effects of fluvoxamine and amitriptyline on autonomic functions in healthy volunteers","volume":"42","author":"Flett","year":"1992","journal-title":"Eur J Clin Pharmacol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000117994","article-title":"Influence of single doses of dothiepin and amitriptyline on physiological measures and psychomotor performance in normal young and elderly volunteers","volume":"10","author":"Ogura","year":"1983","journal-title":"Neuropsychobiology."},{"key":"B209","first-page":"513","article-title":"Cardiovascular effects of mianserin and amitriptyline in healthy volunteers","volume":"18","author":"Wester","year":"1980","journal-title":"Int J Clin Pharmacol Ther Toxicol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1177\/089198879100400409","article-title":"Longitudinal analysis of nortriptyline side effects in elderly depressed patients","volume":"4","author":"Miller","year":"1991","journal-title":"J Geriatr Psychiatry Neurol."},{"key":"B211","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/bmj.1.5852.522","article-title":"Interaction between clonidine and desipramine in man","volume":"1","author":"Briant","year":"1973","journal-title":"Br Med J."},{"key":"B212","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1176\/ajp.155.5.660","article-title":"Cardiovascular effects of fluoxetine in depressed patients with heart disease","volume":"155","author":"Roose","year":"1998","journal-title":"Am J Psychiatry"},{"key":"B213","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/S0002-9149(00)00717-7","article-title":"Comparison of risk of orthostatic hypotension in elderly depressed hypertensive women treated with nortriptyline and thiazides versus elderly depressed normotensive women treated with nortriptyline","volume":"85","author":"Scalco","year":"2000","journal-title":"Am J Cardiol."},{"key":"B214","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/01.HYP.37.2.698","article-title":"Norepinephrine reuptake is impaired in skeletal muscle of hypertensive rats in vivo","volume":"37","author":"Cabassi","year":"2001","journal-title":"Hypertension"},{"key":"B215","doi-asserted-by":"publisher","first-page":"e00602","DOI":"10.1002\/prp2.602","article-title":"The affinity and selectivity of \u03b1-adrenoceptor antagonists, antidepressants, and antipsychotics for the human \u03b11A, \u03b11B, and \u03b11D-adrenoceptors","volume":"8","author":"Proudman","year":"2020","journal-title":"Pharmacol Res Perspect."},{"key":"B216","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nrn1846","article-title":"New approaches to antidepressant drug discovery: beyond monoamines","volume":"7","author":"Berton","year":"2006","journal-title":"Nat Rev Neurosci."},{"key":"B217","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0895-7061(96)00094-5","article-title":"Age-related changes in interstitial norepinephrine. A microdialysis study in spontaneously hypertensive rats","volume":"9","author":"Cabassi","year":"1996","journal-title":"Am J Hypertens."},{"key":"B218","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.euroneuro.2017.05.007","article-title":"Tranylcypromine in mind (Part I): review of pharmacology","volume":"27","author":"Ulrich","year":"2017","journal-title":"Eur Neuropsychopharmacol."},{"key":"B219","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/00004714-198502000-00002","article-title":"Adverse reactions to monoamine oxidase inhibitors. Part II. Treatment correlates and clinical management","volume":"5","author":"Rabkin","year":"1985","journal-title":"J Clin Psychopharmacol."},{"key":"B220","first-page":"119","article-title":"Effects of amitriptyline, fluoxetine, tranylcypromine and venlafaxine on rat vascular smooth muscle in vitro\u2013the role of the endothelium","volume":"63","author":"Ribback","year":"2012","journal-title":"J Physiol Pharmacol."},{"key":"B221","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s12012-018-9476-9","article-title":"Myocardial injury from tranylcypromine-induced hypertensive crisis secondary to excessive tyramine intake","volume":"18","author":"Salter","year":"2018","journal-title":"Cardiovasc Toxicol."},{"key":"B222","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s13181-010-0101-y","article-title":"Phenelzine-induced myocardial injury: a case report","volume":"6","author":"Ngo","year":"2010","journal-title":"J Med Toxicol."},{"key":"B223","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0091-3057(99)00016-7","article-title":"Oral versus transdermal selegiline: antidepressant-like activity in rats","volume":"63","author":"Gordon","year":"1999","journal-title":"Pharmacol Biochem Behav."},{"key":"B224","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jad.2007.04.024","article-title":"The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability","volume":"105","author":"Robinson","year":"2008","journal-title":"J Affect Disord."},{"key":"B225","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/00004714-198912000-00002","article-title":"Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors","volume":"9","author":"Shulman","year":"1989","journal-title":"J Clin Psychopharmacol."},{"key":"B226","first-page":"527","article-title":"Transdermal selegiline for the treatment of major depressive disorder","volume":"3","author":"Lee","year":"2007","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B227","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1001\/archpsyc.1994.03950080019003","article-title":"High-dose selegiline in treatment-resistant older depressive patients","volume":"51","author":"Sunderland","year":"1994","journal-title":"Arch Gen Psychiatry."},{"key":"B228","first-page":"S34","article-title":"Clinical pharmacology of reversible monoamine oxidase-a inhibitors","volume":"2","author":"Bieck","year":"1993","journal-title":"Clin Neuropharmacol."},{"key":"B229","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1007\/BF02246225","article-title":"Biochemistry and pharmacology of moclobemide, a prototype RIMA","volume":"106","author":"Haefely","year":"1992","journal-title":"Psychopharmacology."},{"key":"B230","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3109\/00048679009062902","article-title":"A double blind trial of moclobemide versus amitriptyline in the treatment of depressive disorders","volume":"24","author":"Newburn","year":"1990","journal-title":"Aust N Z J Psychiatry."},{"key":"B231","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/S0140-6736(96)90975-7","article-title":"Hypertension with moclobemide","volume":"347","author":"Laux","year":"1996","journal-title":"Lancet"},{"key":"B232","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/08039480500213725","article-title":"Orthostatic side effects of clomipramine and moclobemide during treatment for depression","volume":"59","author":"Stage","year":"2005","journal-title":"Nord J Psychiatry."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.704281\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T13:58:37Z","timestamp":1725544717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.704281\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,3]]},"references-count":232,"alternative-id":["10.3389\/fcvm.2021.704281"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.704281","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,3]]},"article-number":"704281"}}